039542.76553.8011.040.235.560.361.160.280.021.18Including552.14553.801.660.758.141.527.601.820.096.11LION MREPML-25- 045368.40370.201.800.5414.461.157.960.980.125.56and380.20389.609.400.257.292.011.830.230.093.26Including381.25385.304.050.4714.504.453.980.520.157.01and40 25-046495.80516.2020.400.689.040.885.011.290.064.11Including496.80505.208.401.4216.661.5010.132.900.078.05Note: Reported length is downhole distance; true width based on model projections is estimated as 85% of downhole length1Copper Equiva ...

Core Insights - A significant decline in retirement confidence is observed among middle-income Americans aged 50 to 85, with one in three (32%) feeling less confident in their retirement plans compared to the previous year [1] - Economic factors such as inflation and uncertainty regarding Social Security and Medicare are major contributors to this decline in confidence [1] Economic Concerns - Inflation is the top concern for middle-income Americans, cited by 27%, followed by fears of outliving savings (23%) and potential cuts to Social Security (18%) [1] - 44% of middle-income Americans report increased anxiety about personal finances compared to a year ago, with pre-retirees showing higher anxiety levels [1] Retirement Planning - Many middle-income Americans are uncertain about their financial plans, with 34% feeling less confident in meeting daily financial obligations [1] - Women and pre-retirees are particularly affected, with 25% of women expressing no confidence in having enough for retirement, nearly double the rate of men [1] Government Program Confidence - Confidence in Social Security and Medicare is waning, with 43% of respondents less confident in Social Security's availability and 47% believing Medicare benefits will be cut [1] - There is a significant knowledge gap regarding long-term care financing, with 49% expecting Medicare to cover all needs despite its limitations [1] Survey Methodology - The survey was conducted by Harris Poll among 500 U.S. respondents aged 50 to 85 with household incomes between $50,000 and $100,000, and less than $1 million in investable assets [1]

Core Insights - NeuroSense Therapeutics announced a statistically significant 65% reduction in the risk of death and a median survival benefit of over 14 months for patients with ALS treated with PrimeC [1] Group 1: Clinical Trial Results - The updated analysis from the PARADIGM Phase 2b clinical trial shows that patients receiving PrimeC had a median survival of 36.3 months compared to 21.4 months for those on placebo, indicating a 70% increase in median survival [1] - The survival benefit was consistent over time, with a log-rank test showing statistical significance (p = 0.0218) [1] - A Cox proportional hazards model indicated that PrimeC treatment was associated with a hazard ratio of 0.35, reflecting a 65% reduction in the risk of death compared to placebo (p = 0.0037) [1] Group 2: Company Overview - NeuroSense is a late-stage clinical biotechnology company focused on developing treatments for neurodegenerative diseases, including ALS, Alzheimer's, and Parkinson's [1] - The company aims to address significant unmet medical needs in neurodegenerative diseases, which currently have limited effective therapeutic options [1] - NeuroSense's strategy involves developing combined therapies targeting multiple pathways associated with these diseases [1] Group 3: Product Information - PrimeC is NeuroSense's lead drug candidate, a novel extended-release oral formulation combining ciprofloxacin and celecoxib, designed to target mechanisms contributing to neuron degeneration and inflammation [1] - The company continues to engage with regulatory authorities to advance PrimeC into pivotal late-stage development, reinforcing the clinical and regulatory foundation for the drug [1]

Core Viewpoint - Hagens Berman is investigating Zimmer Biomet Holdings, Inc. (ZBH) due to concerns over the company's "high confidence" assurances regarding its 2025 revenue targets following a 15% stock decline and reduced revenue guidance [1] Group 1: Investigation Focus - The investigation examines whether Zimmer Biomet's senior management misled investors about the stability of its international business, particularly in emerging markets [1] - The firm is looking into potential violations of federal securities laws related to overly optimistic guidance while concealing operational disruptions [1] Group 2: Recent Developments - On November 5, 2025, Zimmer Biomet reported a year-over-year organic revenue growth of only 5%, significantly missing its forecast and reducing its top-line organic revenue growth forecast to 4% [1] - The company disclosed distributor order cancellations in emerging markets, particularly in the Middle East and Eastern Europe, and acknowledged serious headwinds in Latin America [1] - Following these revelations, CEO Ivan Tornos stated the need for more measured external commentary, which contributed to the 15% drop in stock price on the same day [1] Group 3: Previous Assurances - In an August 7, 2025 earnings call, management expressed "very high" confidence in achieving a year-over-year organic revenue growth forecast of 3.5% to 4.5%, attributing it to emerging markets distributor purchases [1] - These optimistic statements led to a 7% increase in the company's share price on that day [1]

Bank of America Launches Art Consulting Service [Accessibility Statement] Skip NavigationNew Offering Helps Bank of America Private Bank and Merrill Clients Build Art LegaciesNEW YORK, Feb. 18, 2026 /PRNewswire/ -- Bank of America Private Bank today announced the launch of its [Art Consulting service], designed to help Private Bank and Merrill clients navigate the complex and often opaque art market. This new offering provides collectors with trusted, unbiased guidance to help them curate and manage collect ...

Core Insights - LPL Financial and Simplicity Group have formed a strategic relationship to enhance insurance capabilities and support for LPL advisors, effective May 1, 2026 [1] - Simplicity will serve as LPL's preferred Brokerage General Agency, providing advanced technology and comprehensive insurance resources [1] - The partnership aims to improve service experiences for clients seeking protection solutions and offers a broad suite of offerings for high-net-worth clients [1] Company Overview - LPL Financial is a leading wealth management firm supporting over 32,000 financial advisors and approximately 1,200 financial institutions, managing around $2.4 trillion in brokerage and advisory assets for about 8 million Americans [1] - Simplicity Group is recognized as a leading partner for advisors and financial institutions, focusing on wealth accumulation and financial protection products [1] Strategic Benefits - The agreement allows LPL to transition its internal insurance business to Simplicity, creating a unified experience for advisors and clients [1] - This strategic shift enables LPL to reinvest in delivering greater value, flexibility, and improved features for advisors and institutions [1]

Levi & Korsinsky Reminds Paysafe Limited Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of April 7, 2026 - PSFE [Accessibility Statement] Skip NavigationNEW YORK, Feb. 18, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Paysafe Limited ("Paysafe Limited" or the "Company") (NYSE: PSFE) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Paysafe Limited investors who were adversely affected by alleged securities ...

Levi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Picard Medical, Inc.(PMI) Shareholders [Accessibility Statement] Skip NavigationNEW YORK, Feb. 18, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Picard Medical, Inc. ("Picard Medical, Inc." or the "Company") (NYSE: PMI) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Picard Medical, Inc. investors who were adversely affected by alleged securities fraud be ...

Klarna Group plc Class Action: Levi & Korsinsky Reminds Klarna Group plc Investors of the Pending Class Action Lawsuit with a Lead Plaintiff Deadline of February 20, 2026 - KLAR [Accessibility Statement] Skip NavigationNEW YORK, Feb. 18, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Klarna Group plc ("Klarna Group plc" or the "Company") (NYSE: KLAR) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Klarna Group plc investors who were a ...

Fermi Inc. Securities Fraud Class Action Lawsuit Pending: Contact Levi & Korsinsky Before March 6, 2026 to Discuss Your Rights - FRMI [Accessibility Statement] Skip NavigationNEW YORK, Feb. 18, 2026 /PRNewswire/ -- Levi & Korsinsky, LLP notifies investors in Fermi Inc. ("Fermi Inc." or the "Company") (NASDAQ: FRMI) of a class action securities lawsuit.CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Fermi Inc. investors who were adversely affected by alleged securities fraud. This lawsuit ...